PE20181020A1 - MUCLEAR RECEIVER MODULATORS - Google Patents

MUCLEAR RECEIVER MODULATORS

Info

Publication number
PE20181020A1
PE20181020A1 PE2017002535A PE2017002535A PE20181020A1 PE 20181020 A1 PE20181020 A1 PE 20181020A1 PE 2017002535 A PE2017002535 A PE 2017002535A PE 2017002535 A PE2017002535 A PE 2017002535A PE 20181020 A1 PE20181020 A1 PE 20181020A1
Authority
PE
Peru
Prior art keywords
cra
muclear
nra
present
halo
Prior art date
Application number
PE2017002535A
Other languages
Spanish (es)
Inventor
Maria A Argiriadi
Eric C Breinlinger
Kevin P Cusack
Adrian D Hobson
Dominique Potin
Martine Barth
Jerôme Amaudrut
Olivia Poupardin
Laurent Mounier
Michael E Kort
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20181020A1 publication Critical patent/PE20181020A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presenten invencion refiere un compuesto de formula (I) en donde W es C o CRa; A y E son independientemente C o N con la condicion de que no sean ambos N; V es CR3 o N; X es CRa, NRa, N u O; Y es C, CRa, NRa,N, O o S; Z es CR3 o N; Cy es un anillo aromatico de 6 miembros, heteroaromatico o parcialmente sustituido con R1 o R2; L1 es -CH(Rb)-, -C(O)-, entre otros; L2 es -C(O)-, -O-, entre otros; R1 y R2 son independientemente halo, cicloalquilo (C3-C6), entre otros; R3 es H, CF3, CN, halo, entre otros; R4 es H, -OH, entre otros; Ra es H, -C(O)CH3, alquilo (C1-C6), entre otros: Rb es H,F,OH, entre otros. Es compuesto preferido: acido 1-(2,4-dicloro-3-((1,4-dimetil-6-(trifluorometil)-1H-indol-2-il)metil)benzoil)piperidin-4-carboxilico; entre otros. La presente invencion es util para el tratamiento de enfermedades inflamatorias y autoinmunes, como es el caso de artritis reumatoide, colitis ulcerosa, entre otras referidas en la invencionThe present invention relates to a compound of formula (I) wherein W is C or CRa; A and E are independently C or N provided they are not both N; V is CR3 or N; X is CRa, NRa, N or O; Y is C, CRa, NRa, N, O, or S; Z is CR3 or N; Cy is a 6-membered aromatic ring, heteroaromatic or partially substituted with R1 or R2; L1 is -CH (Rb) -, -C (O) -, among others; L2 is -C (O) -, -O-, among others; R1 and R2 are independently halo, (C3-C6) cycloalkyl, among others; R3 is H, CF3, CN, halo, among others; R4 is H, -OH, among others; Ra is H, -C (O) CH3, (C1-C6) alkyl, among others: Rb is H, F, OH, among others. The preferred compound is: 1- (2,4-dichloro-3 - ((1,4-dimethyl-6- (trifluoromethyl) -1H-indol-2-yl) methyl) benzoyl) piperidine-4-carboxylic acid; among others. The present invention is useful for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, among others referred to in the invention.

PE2017002535A 2015-06-09 2016-06-08 MUCLEAR RECEIVER MODULATORS PE20181020A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators

Publications (1)

Publication Number Publication Date
PE20181020A1 true PE20181020A1 (en) 2018-06-27

Family

ID=54293273

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002535A PE20181020A1 (en) 2015-06-09 2016-06-08 MUCLEAR RECEIVER MODULATORS

Country Status (3)

Country Link
AR (1) AR104934A1 (en)
PE (1) PE20181020A1 (en)
WO (1) WO2016198908A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108689942B (en) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 Nitrogen-containing bicyclic compound, and preparation method and application thereof
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
BR112022020131A2 (en) 2020-04-06 2022-11-29 Basf Se COMPOUND OF THE FORMULA, MIXTURE OF PESTICIDES, USE OF COMPOUNDS OF THE FORMULA, METHODS FOR COMBAT OR CONTROL OF INVERTEBRATE PEST AND PROTECTION OF GROWING PLANTS AND SEEDS
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN116283753A (en) * 2023-03-20 2023-06-23 武汉朗克环境科技有限公司 Trifluoromethyl pyridine amide derivative and preparation method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
BR0317525A (en) 2002-12-20 2005-11-16 Pharmacia Corp Acyclic pyrazole compounds, therapeutic and pharmaceutical composition, kit, as well as their uses
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
JP2008504266A (en) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー Compounds and methods for treating dyslipidemia
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
PL1807072T3 (en) 2004-10-29 2009-06-30 Lilly Co Eli Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
BRPI1007923A2 (en) 2009-02-06 2020-08-25 Elan Pharmaceuticals, Inc compound, pharmaceutical composition, methods for treating a neurodegenerative disease, and for reducing the concentration of p-cjun in brain tissue of an individual in need thereof, use of a compound, and, in vitro method
AU2010295481A1 (en) 2009-09-18 2012-03-08 Zalicus Pharmaceuticals Ltd. Aryl sulphone derivatives as calcium channel blockers
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
KR20140082643A (en) 2011-07-25 2014-07-02 알러간, 인코포레이티드 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
CN105531274A (en) * 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 Keto-imidazopyridine derivatives as rorc modulators

Also Published As

Publication number Publication date
AR104934A1 (en) 2017-08-23
WO2016198908A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
PE20181020A1 (en) MUCLEAR RECEIVER MODULATORS
PE20181093A1 (en) HETEROCYCLIC COMPOUNDS AND USES OF THEM
PE20161572A1 (en) COMPOUNDS AS ROR GAMMA MODULATORS
PE20141726A1 (en) HETEROCYCLYLAMINES AS 3K PI INHIBITORS
PE20161368A1 (en) DIACILGLICEROL ACILTRANFERASE 2 INHIBITORS
PE20190518A1 (en) DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS
ECSP18094790A (en) PYRIDINES SUBSTITUTED WITH HETEROARYL AND METHODS OF USE CROSS REFERENCE TO RELATED REQUESTS
PE20131343A1 (en) DERIVATIVES OF BENZOIC ACID
AR104388A1 (en) INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
PE20170682A1 (en) PYRIMIDINE DERIVATIVES SUBSTITUTED WITH OPTIONALLY CONDENSED HETERO CYCLYL USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES
UY37073A (en) SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
PE20141204A1 (en) NOVEL COMPOUNDS AS INHIBITORS OF DIACILGLICEROL ACILTRANSFERASE
CU24605B1 (en) PYRIMIDIN-2-IL AMINO-1H-PYRAZOLE USEFUL AS LRRK2 INHIBITORS
PE20150182A1 (en) PHENOXYETHYL PIPERIDINE COMPOUNDS
UY36244A (en) DERIVATIVES OF PYRIMIDINONE AS INHIBITORS OF THE XIA FACTOR AND / OR THE PLASMA CALICREINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20151144A1 (en) RETINOID RELATED GAMMA RECEPTOR ORPHAN MODULATORS (ROR - GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
PE20161292A1 (en) NICOTINAMIDE COMPOUNDS SUBSTITUTED WITH HETEROARYL
PE20161243A1 (en) FUSED HETEROCYCLIC COMPOUND
PE20181074A1 (en) HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
PE20170267A1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE AS T-RANGE INHIBITORS OF THE RETINOID-RELATED ORPHAN RECEPTOR (ROR)
PE20070854A1 (en) HETEROCYCLES COMPOUNDS AS AGONISTS OF THE NICOTINIC ACID RECEPTOR
GT201400289A (en) "DIMETIL-BENZOIC ACID COMPOUNDS"
PE20142081A1 (en) QUINURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE OF THEM
PE20171649A1 (en) TRIFLUOROMETHYL ALCOHOLS AS ROR MODULATORS (gamma) T
PE20161444A1 (en) 1,2-CYCLOPENTANES SUBSTITUTED AS OREXIN RECEPTOR ANTAGONISTS